Edition:
United Kingdom

Profile: argenx SE (ARGX.OQ)

ARGX.OQ on NASDAQ Stock Exchange Global Select Market

140.35USD
7:21pm BST
Change (% chg)

$0.66 (+0.47%)
Prev Close
$139.69
Open
$139.10
Day's High
$140.59
Day's Low
$138.81
Volume
14,047
Avg. Vol
50,961
52-wk High
$142.32
52-wk Low
$63.81

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Company Address

argenx SE

Willemstraat 5
BREDA     4811 AH
P: +3176.3030488

Company Web Links